💊 Arzneimittel A-Z 🧬 Targets 🛠 Werkzeuge 📚 Leitfäden
Alle Arzneimittel Arzneimittelklassen Therapeutische Bereiche Nebenwirkungen
Leitfäden Glossar Zeitleiste
Vergleiche Arzneimittelreisen Arzneimittel-Wirkstoffgruppen
🇺🇸 English 🇰🇷 한국어 🇯🇵 日本語 🇨🇳 中文简体 🇪🇸 Español 🇧🇷 Português 🇮🇳 हिन्दी 🇸🇦 العربية 🇫🇷 Français 🇷🇺 Русский 🇩🇪 Deutsch 🇹🇷 Türkçe 🇻🇳 Tiếng Việt 🇮🇩 Bahasa Indonesia 🇹🇭 ไทย

Clarithromycin

CHEMBL1741 Phase 4 Zugelassen Small molecule
Half-Life
—
Bioavailability
—
Protein Binding
—
Molecular Weight
748.0 g/mol
LogP
3.2
Phase
4

A macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, with enhanced stability and broader activity compared to erythromycin. It is used for respiratory tract infections, Helicobacter pylori eradication (in combination regimens), and atypical mycobacterial infections. It is a potent CYP3A4 inhibitor with numerous clinically significant drug interactions.

Molekularmasse

748,0000 g/mol

LogP

3,20

TPSA

183,00 Ų

Lipinski-Regel der Fünf

Nicht bestanden

Therapeutische Bereiche

Cardiovascular Disease Hematology Non-Small Cell Lung Cancer Asthma Immunology Parkinson's Disease Epilepsy Gastroesophageal Reflux Disease Multiple Sclerosis Obesity Lymphoma Tuberculosis Atrial Fibrillation Prostate Cancer Leukemia

Wirkmechanismus

Binds to the 50S ribosomal subunit of susceptible bacteria, blocking the translocation step of protein synthesis by interfering with transpeptidation and translocation. This results in bacteriostatic inhibition of protein production.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Binds to the 50S ribosomal subunit of susceptible bacteria, blocking the translocation step of protein synthesis by interfering with transpeptidation and translocation. This results in bacteriostatic inhibition of protein production.

2D-Struktur

SVG PNG

Cite this structure


                        

                            
                            
                        

                    

                


                
                

                    

                    

                        
Embed this structure

                        

                        

                            
                            
                        

                    

                

                

                
                

                    
SMILES

                    
CC[C@H]1OC(=O)[C@H](C)[C@@H](O[C@H]2C[C@@](C)(OC)[C@@H](O)[C@H](C)O2)[C@H](C)[C@@H](O[C@@H]2O[C@H](C)C[C@H](N(C)C)[C@H]2O)[C@](C)(OC)C[C@@H](C)C(=O)[C@H](C)[C@@H](O)[C@]1(C)O

                

                

                
                

                    
InChI

                    
InChI=1S/C38H69NO13/c1-15-26-38(10,45)31(42)21(4)28(40)19(2)17-37(9,47-14)33(52-35-29(41)25(39(11)12)16-20(3)48-35)22(5)30(23(6)34(44)50-26)51-27-18-36(8,46-13)32(43)24(7)49-27/h19-27,29-33,35,41-43,45H,15-18H2,1-14H3/t19-,20-,21+,22+,23-,24+,25+,26-,27+,29-,30+,31-,32+,33-,35+,36-,37-,38-/m1/s1

                

                

                

                    
                    

                        
Molecular Formula

                        
C38H69NO13

                    

                    
                    

                        
HBD / HBA

                        
4 / 14

                    

                    
                    

                        
Rotierbare Bindungen

                        
8

                    

                    
                    
                    

                        
Schwere Atome

                        
52

                    

                    
                

            


            
            

                
                


    
    
        
    
    
    
No targets recorded

    
    
Target interaction data is not yet available for this drug.

    



                
            


            
            

                
                


    
    
        
    
    
    
No interactions recorded

    
    
Drug interaction data is not yet available for this compound.

    



                
            


            
            

                
                


    
    
        
    
    
    
No side effects recorded

    
    
Side effect data is not yet available for this drug.

    



                
            


            
            
            

                
Häufig gestellte Fragen

                

                    
                    

                        
                        

                            
A macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, with enhanced stability and broader activity compared to erythromycin. It is used for respiratory tract infections, Helicobacter pylori eradication (in combination regimens), and atypical mycobacterial infections. It is a potent CYP3A4 inhibitor with numerous clinically significant drug interactions.

                        

                    

                    

                    

                    
                    

                        
                        

                            
Binds to the 50S ribosomal subunit of susceptible bacteria, blocking the translocation step of protein synthesis by interfering with transpeptidation and translocation. This results in bacteriostatic inhibition of protein production.

                        

                    

                    

                    

                    

                        
                        

                            
Yes, Clarithromycin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

                        

                    

                

            

            

            
            

            
            

            
            
{# References & Data Sources section for drug detail pages.
   Renders standard pharmacological database links plus the drug's data_sources field. #}


    
References & Data Sources

    
    
        
        
  • 
            
            
                ChEMBL — European Bioinformatics Institute (EBI).
                CHEMBL1741.
                Open-access bioactivity database.
            
        
    • 
        
        
        
  • 
            
            
                PubChem — National Center for Biotechnology Information (NCBI).
                CID 84029.
                Chemical information database.
            
        
    • 
        
        
        
        
    

    
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.




        


        
        
    


    



    
Medizinischer Haftungsausschluss

    

        This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.
    

    

        Data sources:
        ChEMBL,
        PubChem,
        DailyMed.